Axiom Investors’s Castle Biosciences CSTL Stock Holding History

Axiom Investors’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-31,310	Closed	-$2.3M	–	123
2021 Q2	$2.3M	Sell	31,310 -17,370	-36%	-$1.15M	0.04%	113
2021 Q1	$3.33M	Sell	48,680 -9,145	-16%	-$687K	0.06%	107
2020 Q4	$3.88M	Buy	+57,825	New	+$3.13M	0.06%	95

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Axiom Investors's CSTL Position: Q3 2021 in Review

Axiom Investors sold out of Castle Biosciences (CSTL) in Q3 2021, closing a stake of 31,310 shares — an estimated $2.3M sold.

Axiom Investors first reported a position in CSTL in Q4 2020 and held it in 3 quarters. The position peaked at $3.88M in Q4 2020. 188 funds tracked by Wall St. Rank hold CSTL as of Q3 2021.

Axiom Investors reported no remaining Castle Biosciences position as of Q3 2021 after selling out during the quarter.
Axiom Investors sold 31,310 Castle Biosciences shares in Q3 2021, an estimated $2.3M.
Axiom Investors first reported a position in Castle Biosciences in Q4 2020 and held it in 3 quarters.
Axiom Investors's Castle Biosciences position peaked at $3.88M in Q4 2020.
188 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2021.

Based on Axiom Investors's 13F filing for Q3 2021, filed 12 Nov 2021.